HUGE FSD Pharma Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

HUGE [NASD]

FSD Pharma Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | Canada

statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	13.19%	Shs Outstand	14.72M	Perf Week	-19.03%
Market Cap	31.95M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.19M	Perf Month	-21.94%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	0.74%	Perf Quarter	-45.75%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-33.43%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-73.67%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	2.06 - 14.00	Perf YTD	-60.03%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-86.14%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	-5.83%	ATR	0.16
Employees	17	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	23.33	Volatility	5.89% 5.41%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.48	Prev Close	2.17
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	736.22K	Price	1.94
Recom	-	SMA20	-24.76%	SMA50	-29.48%	SMA200	-50.30%	Volume	343,047	Change	-10.60%

Oct-16-20 07:30AM	FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering Business Wire -16.41%
Oct-05-20 07:30AM	FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients Business Wire
Sep-28-20 02:30AM	FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients ACCESSWIRE
Aug-31-20 02:30AM	FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19 Business Wire
Aug-20-20 05:45AM	HUGE.CN: FSD Pharmas FSDs Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA. Zacks Small Cap Research +10.51%
Aug-07-20 05:45PM	FSD Pharma Reports Second Quarter 2020 Financial Results Business Wire
05:45PM	FSD Pharma Reports Second Quarter 2020 Financial Results ACCESSWIRE
Aug-06-20 05:00PM	FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors Business Wire
05:00PM	FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors ACCESSWIRE
Jul-31-20 04:49PM	FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video Newsfile -14.79%
09:00AM	FSD Pharma Inc. Announces US$10 Million Registered Direct Offering ACCESSWIRE
Jul-30-20 02:30AM	FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc. Business Wire +13.90%
Jul-13-20 02:30AM	FSD Pharma Announces US$20M At-The-Market Offering Business Wire
02:30AM	FSD Pharma Announces US$20M At-The-Market Offering ACCESSWIRE
Jun-23-20 09:00AM	InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com Newsfile -7.67%
Jun-22-20 02:30AM	FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA Business Wire
Jun-09-20 11:39AM	FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors CNW Group -7.74%
05:47AM	HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients Zacks Small Cap Research
Jun-04-20 09:43AM	FSD Pharma Inc. Announces C$10.125 Million Private Placement CNW Group -28.96%
Jun-03-20 04:20PM	Covid Report: Small Biotech Doubles On Plans To Test A Coronavirus Drug Investor's Business Daily +138.39%
02:30AM	FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis CNW Group
02:30AM	FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis Business Wire
May-21-20 08:30AM	FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc. CNW Group -6.75%
08:30AM	FSD Pharma Monetizes Non-Core Asset With Sale of Partial Equity Stake in Pharmadrug Inc. Business Wire
May-14-20 05:12PM	FSD Pharma Reports First Quarter 2020 Financial Results CNW Group
Mar-23-20 09:17AM	FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario CNW Group
Mar-10-20 09:00AM	InvestmentPitch Media Video Discusses FSD Pharma's Initiation of Phase 1 In-Human Safety & Tolerability Study of Dosing Ultra Micro-PEA for Targeting CB2 Receptors at Alfred Hospital in Australia - Video Available on Investmentpitch.com Newsfile
Mar-09-20 08:30AM	FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA) CNW Group
08:30AM	FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA) Business Wire
Mar-06-20 01:14PM	FSD Pharma Inc., Worldwide License of Natural Fatty Acid, CEO Clip Video Newsfile -10.92%
Mar-04-20 02:30AM	FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020 CNW Group +11.76%
02:30AM	FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020 Business Wire

FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience